Longeveron Competitors

Longeveron (NASDAQ:LGVN) and Terns Pharmaceuticals (NASDAQ:TERN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, risk, earnings and dividends.

Valuation & Earnings

This table compares Longeveron and Terns Pharmaceuticals' revenue, earnings per share and valuation.

Profitability

This table compares Longeveron and Terns Pharmaceuticals' net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Longeveron and Terns Pharmaceuticals, as reported by MarketBeat.com.

Terns Pharmaceuticals has a consensus target price of $30.50, indicating a potential upside of 61.12%. Given Terns Pharmaceuticals' higher possible upside, analysts clearly believe Terns Pharmaceuticals is more favorable than Longeveron.

Summary

Terns Pharmaceuticals beats Longeveron on 2 of the 2 factors compared between the two stocks.

Longeveron (NASDAQ:LGVN) and Angion Biomedica (NASDAQ:ANGN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, risk, earnings and dividends.

Valuation & Earnings

This table compares Longeveron and Angion Biomedica's revenue, earnings per share and valuation.

Profitability

This table compares Longeveron and Angion Biomedica's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Longeveron and Angion Biomedica, as reported by MarketBeat.com.

Angion Biomedica has a consensus target price of $59.3333, indicating a potential upside of 283.29%. Given Angion Biomedica's higher possible upside, analysts clearly believe Angion Biomedica is more favorable than Longeveron.

Summary

Angion Biomedica beats Longeveron on 2 of the 2 factors compared between the two stocks.

Longeveron (NASDAQ:LGVN) and Sensei Biotherapeutics (NASDAQ:SNSE) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, risk, earnings and dividends.

Valuation & Earnings

This table compares Longeveron and Sensei Biotherapeutics' revenue, earnings per share and valuation.

Profitability

This table compares Longeveron and Sensei Biotherapeutics' net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Longeveron and Sensei Biotherapeutics, as reported by MarketBeat.com.

Sensei Biotherapeutics has a consensus target price of $29.50, indicating a potential upside of 108.78%. Given Sensei Biotherapeutics' higher possible upside, analysts clearly believe Sensei Biotherapeutics is more favorable than Longeveron.

Summary

Sensei Biotherapeutics beats Longeveron on 2 of the 2 factors compared between the two stocks.

Longeveron (NASDAQ:LGVN) and NexImmune (NASDAQ:NEXI) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, risk, earnings and dividends.

Valuation & Earnings

This table compares Longeveron and NexImmune's revenue, earnings per share and valuation.

Profitability

This table compares Longeveron and NexImmune's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Longeveron and NexImmune, as reported by MarketBeat.com.

NexImmune has a consensus target price of $33.3333, indicating a potential upside of 86.74%. Given NexImmune's higher possible upside, analysts clearly believe NexImmune is more favorable than Longeveron.

Summary

NexImmune beats Longeveron on 2 of the 2 factors compared between the two stocks.

Longeveron (NASDAQ:LGVN) and Landos Biopharma (NASDAQ:LABP) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, risk, earnings and dividends.

Valuation & Earnings

This table compares Longeveron and Landos Biopharma's revenue, earnings per share and valuation.

Profitability

This table compares Longeveron and Landos Biopharma's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Longeveron and Landos Biopharma, as reported by MarketBeat.com.

Landos Biopharma has a consensus target price of $25.50, indicating a potential upside of 156.80%. Given Landos Biopharma's higher possible upside, analysts clearly believe Landos Biopharma is more favorable than Longeveron.

Summary

Landos Biopharma beats Longeveron on 2 of the 2 factors compared between the two stocks.

Longeveron (NASDAQ:LGVN) and Portage Biotech (NASDAQ:PRTG) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, risk, earnings and dividends.

Profitability

This table compares Longeveron and Portage Biotech's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Longeveron and Portage Biotech's revenue, earnings per share and valuation.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Longeveron and Portage Biotech, as reported by MarketBeat.com.